http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2564077-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b7317808024e524eea40a6c5a5ad6a22 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-1038 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H20-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H10-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H70-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-103 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H10-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H20-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H50-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H70-60 |
| filingDate | 2010-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05f4ee8ec111880c72f319bef85b4c7f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e752943acb72bf1743cd2af90bdf79c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef3801b007853d8c7681f464bba64440 |
| publicationDate | 2015-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2564077-C2 |
| titleOfInvention | Probability of injury to normal tissues, adapted with account of markers |
| abstract | FIELD: medicine. n SUBSTANCE: group of inventions relates to medicine, oncology and deals with the formation of a patient's individual therapy plan. The method includes the formation of an initial plan of therapy by means of a normal tissue complication probability (NTCP) model and a tumour control probability (TCP) model for a target area. NTCP and TCP models are adapted on the basis of initial quantitative values of the patient's set of biomarkers. After the application of the initial therapy a corrected plan of therapy is formed by means of NTCP and TCP models, adapted on the basis of updated after the application of therapy quantitative values of the set of biomarkers. The initial and updated NTCP models are expressed in the form of the function of an equivalent uniform dose (EUD) modified with the application of a scalar value. The values of the set of biomarkers represent determined by an analysis values of parameters from the group: levels of Hb, CRP, PSA, TNF-α, ferritin, transferritin, LDH, IL-6, hepsidin, creatinine, glucose, HbA1c, complexes, binding DNA ends (DNA-EBC), HIF-lα, galectine-1, CAP43 and/or NDRG1; length of a telomere; type of the tumour; tumour degree; tumour stage; location of the initial tumour; degree of malignancy by the Gleason scale; data of the collagen level analysis; previous treatment in the form of abdominal surgery, hormonal drug therapy, anticoagulation drug therapy; presence of diabetes; patient's age. A machine-readable data carrier, which contains a programme, a controlling processor for carrying out the said method and a processor for carrying out method stages, is used. n EFFECT: individual adaptive planning of therapy for an oncologic patient with the optimisation of a probability of injury to normal tissue and neutralisation of the tumour in accordance with the individual markers for each patient is provided. n 8 cl, 6 dwg |
| priorityDate | 2009-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 164.